Citalopram-d3 (hydrobromide)

• UNSPSC Description:

  Citalopram-d3 ((±)-Citalopram-d3) hydrobromide is deuterium labeled Citalopram (hydrobromide). Citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI). Citalopram hydrobromide inhibits 5-HT uptake into synaptosomes with an IC50 of 1.8 nM. Citalopram hydrobromideinhibits the 5-HT uptake in rabbit blood platelets with an IC50 of 14 nM. Antidepressant effect[1][2].

• Target Antigen:

  Autophagy; Isotope-Labeled Compounds; Serotonin Transporter

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Autophagy;Neuronal Signaling;Others

• Field of Research:

  Neurological Disease;Cancer

• Smiles:

  N#CC1=CC2=C(C(CCCN(C)C([2H])([2H])[2H])(C3=CC=C(F)C=C3)OC2)C=C1.Br

• Molecular Weight:

  408.32

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]J Hyttel. Citalopram--pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(3):277-95.|[3]Laurent Sakka, et al. Assessment of citalopram and escitalopram on neuroblastoma cell lines. Cell toxicity and gene modulation. Oncotarget. 2017 Jun 27;8(26):42789-42807.|[4]F Pollier, et al. Serotonin reuptake inhibition by citalopram in rat strains differing for their emotionality. Neuropsychopharmacology. 2000 Jan;22(1):64-76.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported